Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia.
Noelle V FreyPublished in: Blood (2022)
In October 2021, brexucabtagene autoleucel became the first anti-CD19 chimeric antigen receptor T-cell product to receive approval from the Food and Drug Administration to treat adults with relapsed and refractory B-cell acute lymphoblastic leukemia. The approval is based on results from the Zuma-3 trial and significantly widens treatment options for this patient population. In this article, we review outcomes from this study and its implications.
Keyphrases
- drug administration
- acute lymphoblastic leukemia
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- multiple myeloma
- diffuse large b cell lymphoma
- liver failure
- hodgkin lymphoma
- clinical trial
- bone marrow
- study protocol
- case report
- phase iii
- randomized controlled trial
- aortic dissection
- climate change
- nk cells